These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32920821)

  • 21. An improved multiply robust estimator for the average treatment effect.
    Wang C; Wei K; Huang C; Yu Y; Qin G
    BMC Med Res Methodol; 2023 Oct; 23(1):231. PubMed ID: 37821829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subclassification estimation of the weighted average treatment effect.
    Choi BY
    Biom J; 2021 Dec; 63(8):1706-1728. PubMed ID: 34270815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Causal inference with noisy data: Bias analysis and estimation approaches to simultaneously addressing missingness and misclassification in binary outcomes.
    Shu D; Yi GY
    Stat Med; 2020 Feb; 39(4):456-468. PubMed ID: 31802532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Model misspecification and robustness in causal inference: comparing matching with doubly robust estimation.
    Waernbaum I
    Stat Med; 2012 Jul; 31(15):1572-81. PubMed ID: 22359267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Landmark Prediction of Long Term Survival Incorporating Short Term Event Time Information.
    Parast L; Cheng SC; Cai T
    J Am Stat Assoc; 2012; 107(500):1492-1501. PubMed ID: 23293405
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Robust risk prediction with biomarkers under two-phase stratified cohort design.
    Payne R; Yang M; Zheng Y; Jensen MK; Cai T
    Biometrics; 2016 Dec; 72(4):1037-1045. PubMed ID: 27037494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Censored quantile regression based on multiply robust propensity scores.
    Wang X; Qin G; Song X; Tang Y
    Stat Methods Med Res; 2022 Mar; 31(3):475-487. PubMed ID: 34903106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Related causal frameworks for surrogate outcomes.
    Joffe MM; Greene T
    Biometrics; 2009 Jun; 65(2):530-8. PubMed ID: 18759836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using a surrogate with heterogeneous utility to test for a treatment effect.
    Parast L; Cai T; Tian L
    Stat Med; 2023 Jan; 42(1):68-88. PubMed ID: 36372072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical Methods to Evaluate Surrogate Markers.
    Parast L; Tian L; Cai T; Palaniappan L
    Med Care; 2024 Feb; 62(2):102-108. PubMed ID: 38079232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semiparametric inference for surrogate endpoints with bivariate censored data.
    Ghosh D
    Biometrics; 2008 Mar; 64(1):149-56. PubMed ID: 17651457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmented and doubly robust G-estimation of causal effects under a Structural nested failure time model.
    Mertens K; Vansteelandt S
    Biometrics; 2018 Jun; 74(2):472-480. PubMed ID: 28742252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Causal inference for recurrent event data using pseudo-observations.
    Su CL; Platt RW; Plante JF
    Biostatistics; 2022 Jan; 23(1):189-206. PubMed ID: 32432686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonparametric multiple imputation for receiver operating characteristics analysis when some biomarker values are missing at random.
    Long Q; Zhang X; Hsu CH
    Stat Med; 2011 Nov; 30(26):3149-61. PubMed ID: 22025311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leveraging auxiliary data to improve precision in inverse probability-weighted analyses.
    Zalla LC; Yang JY; Edwards JK; Cole SR
    Ann Epidemiol; 2022 Oct; 74():75-83. PubMed ID: 35940394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surrogacy marker paradox measures in meta-analytic settings.
    Elliott MR; Conlon AS; Li Y; Kaciroti N; Taylor JM
    Biostatistics; 2015 Apr; 16(2):400-12. PubMed ID: 25236906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating prognostic accuracy of biomarkers under competing risk.
    Zheng Y; Cai T; Jin Y; Feng Z
    Biometrics; 2012 Jun; 68(2):388-96. PubMed ID: 22150576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G-computation and doubly robust standardisation for continuous-time data: A comparison with inverse probability weighting.
    Chatton A; Borgne FL; Leyrat C; Foucher Y
    Stat Methods Med Res; 2022 Apr; 31(4):706-718. PubMed ID: 34861799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double robust estimator of average causal treatment effect for censored medical cost data.
    Wang X; Beste LA; Maier MM; Zhou XH
    Stat Med; 2016 Aug; 35(18):3101-16. PubMed ID: 26818601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Restricted survival benefit with right-censored data.
    Zhang S; LeBlanc ML; Zhao YQ
    Biom J; 2022 Apr; 64(4):696-713. PubMed ID: 34970772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.